FDA granted Fast Track designation to QTX3034 + cetuximab for KRASG12D-mutant CRC, with or without FOLFOX chemotherapy
“We look forward to presenting new clinical data at ESMO highlighting the potential of QTX3034-based combinations to improve outcomes for patients with KRASG12D-mutant CRC,” said Perry Nisen, M.D., Ph.D., Chief Executive Officer of Quanta. “We are particularly pleased that these data supported the FDA’s decision to grant Fast Track designation for QTX3034 in this patient population. We believe this represents the first Fast Track designation based on clinical data for a KRAS G12D-targeted therapy in CRC, underscoring the significant unmet need in this population and the importance of advancing innovative treatment options for these patients.”
Share:
More News
“We believe TCEs have a powerful role to play in the future of immunotherapy to treat cancer. This collaboration with Gilead provides an opportunity to generate multiple differentiated candidates aimed at difficult-to-address solid tumors and to expand the potential impact of our science, while also advancing our own clinical oncology
“Patients with KRAS G12D-driven cancers deserve an effective, highly targeted therapy suitable for long-term treatment. Today’s first multi-tumor clinical dataset for VS-7375 demonstrates compelling and robust responses across KRAS G12D-mutated cancers, marking an important development milestone and reinforcing our conviction that VS-7375 has the potential to become both a best-in-class
“FDA acceptance of the UGN-103 NDA advances our vision for the next evolution of our portfolio and our continued commitment to transforming the treatment of recurrent LG-IR-NMIBC,” said Liz Barrett, President and CEO, UroGen. “Building on our experience with ZUSDURI (mitomycin) for intravesical solution, UGN-103 combines our proprietary RTGel® technology
“We are honored to be among the six recipients selected for funding through the FDA’s highly competitive Orphan Products Clinical Trials grants program,” said Juan Vera, MD, President and Chief Executive Officer of Marker Therapeutics. “This award represents meaningful independent recognition and external validation of the scientific rationale underlying our